Synvect

Synvect is a biotechnology company focused on eradicating mosquito-borne diseases through innovative biological solutions. Operating in the public health sector, Synvect targets the growing mosquito burden with its next-generation Sterile Insect Technique (ngSIT) and SEPARATOR products. The ngSIT system is engineered to affect only specific mosquito species, such as Aedes aegypti, which are known carriers of diseases like Dengue, Yellow Fever, and Zika. By leveraging the natural mating behaviors of mosquitoes, Synvect's technology aims to suppress and eliminate these targeted species without affecting others. The company serves governments, health organizations, and communities in regions plagued by mosquito-borne illnesses. Synvect's business model revolves around providing safe, economical, and effective mosquito control solutions, capitalizing on a straightforward regulatory path for its products. The company generates revenue through the sale and distribution of its specialized mosquito control systems.

Keywords: biotechnology, mosquito control, public health, ngSIT, Aedes aegypti, disease prevention, species-specific, regulatory, suppression, elimination.